New Evidence on SAPIEN 3 Ultra RESILIA Valve Set to Boost EW Stock

Edwards Lifesciences (EW) has announced one-year, real-world data on its SAPIEN 3 Ultra RESILIA valve at the PCR London Valves 2024. These data add to the extensive body of evidence on the company’s SAPIEN valve platform, backed by multiple years of follow-up and more than 10 years of clinical experience with the RESILIA tissue.The latest development should bolster Edwards’ Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart groups. The findings were simultaneously published in the J ...